Tyrosine

Tyrosine

SCHEMBL3909629

C[C@@H](O)[C@H](N)C(=O)O.NC(=O)CC[C@H](N)C(=O)O.NC(=O)C[C@H](N)C(=O)O.N[C@@H](CO)C(=O)O.N[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.50
ALOX15 P16050 2/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGS1 P23219 2/20 0.37
ALPI P09923 1/20 0.37
PKM P14618 1/20 0.37
XIAP P98170 1/20 0.37
TPH1 P17752 3/20 0.37
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
EGFR P00533 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
HTR2A P28223 1/20 0.36
PTGS2 P35354 1/20 0.36
RECQL P46063 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL3909625 1.00 SLC7A5 (0.50) SLC7A5ALOX15BLMPMP22KMT2A
Tyrosine SCHEMBL1900124 0.95 SLC7A5 (0.45) SLC7A5ALOX15BLMPMP22KMT2A
Tyrosine SCHEMBL2004299 0.92 SLC7A5 (0.42) SLC7A5ALOX15BLMPMP22KMT2A
Tyrosine SCHEMBL26977289 0.91 SLC7A5 (0.60) SLC7A5ALOX15BLMPMP22KMT2A
Tyrosine SCHEMBL8588121 0.91 SLC7A5 (0.49) SLC7A5ALOX15BLMPMP22KMT2A
Tyrosine SCHEMBL8588119 0.91 SLC7A5 (0.49) SLC7A5ALOX15BLMPMP22KMT2A
Tyrosine SCHEMBL20377367 0.89 SLC7A5 (0.63) SLC7A5ALOX15PTGS1ALPIPKM
Tyrosine SCHEMBL27482098 0.87 SLC7A5 (0.55) SLC7A5ALOX15BLMPMP22KMT2A
Tyrosine SCHEMBL4575526 0.87 SLC7A5 (0.67) SLC7A5ALOX15PTGS1ALPIPKM
Tyrosine SCHEMBL8134263 0.87 SLC7A5 (0.67) SLC7A5ALOX15BLMPMP22KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861497-A4 PROTEIN AND ITS USE IN DIAGNOSING ALZHEIMER'S DISEASE NYMOX CORP (CA) 2009-01-28 EP disclosed
WO-2008014603-A2 PEPTIDES EFFECTIVE IN THE TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION OF CELLS NYMOX CORPORATION (CA) 2008-02-07 WO disclosed
EP-1861497-A1 PROTEIN AND ITS USE IN DIAGNOSING ALZHEIMER'S DISEASE NYMOX CORPORATION (CA) 2007-12-05 EP disclosed
WO-2006089422-A1 PROTEIN AND ITS USE IN DIAGNOSING ALZHEIMER'S DISEASE NYMOX CORPORATION (CA) 2006-08-31 WO disclosed
EP-1626984-A1 SPHERON COMPONENTS USEFUL IN DETERMINING COMPOUNDS CAPABLE OF TREATING SYMPTOMS OF ALZHEIMER'S DISEASE Nymox Pharmaceutical Corporation (CA) 2006-02-22 EP disclosed
WO-2004104029-A1 SPHERON COMPONENTS USEFUL IN DETERMINING COMPOUNDS CAPABLE OF TREATING SYMPTOMS OF ALZHEIMER’S DISEASE NYMOX PHARMACEUTICAL CORPORATION (CA) 2004-12-02 WO disclosed
EP-1481007-A2 SPHERON COMPONENTS USEFUL IN DETERMINING COMPOUNDS CAPABLE OF TREATING SYMPTOMS OF ALZHEIMER'S DISEASE, TREATMENTS AND ANIMAL MODELS PRODUCED THEREFROM Nymox Corporation (CA) 2004-12-01 EP disclosed
EP-1417227-A2 PEPTIDES EEFECTIVE IN THE TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION OF CELLS Nymox Corporation (CA) 2004-05-12 EP disclosed
EP-1417228-A2 PEPTIDES EFFECTIVE IN THE TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION OF CELLS NYMOX CORPORATION (CA) 2004-05-12 EP disclosed
EP-1392347-A2 METHOD OF PREVENTING CELL DEATH USING SEGMENTS OF NEURAL THREAD PROTEINS NYMOX CORPORATION (CA) 2004-03-03 EP disclosed
US-6165753-A Cyclin E genes and proteins AMGEN INC. (US) 2000-12-26 US disclosed
EP-1045907-A1 DKR POLYPEPTIDES Amgen Inc. (US) 2000-10-25 EP disclosed
WO-2000058479-A1 BETA SECRETASE GENES AND POLYPEPTIDES AMGEN INC. (US) 2000-10-05 WO disclosed
WO-2000046240-A2 POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE AMGEN INC. (US) 2000-08-10 WO disclosed
WO-2000044898-A2 NOVEL AGOUTI AND AGOUTI-RELATED PEPTIDE ANALOGS AMGEN INC. (US) 2000-08-03 WO disclosed
WO-2000034475-A2 GRNF4, A GDNF-RELATED NEUROTROPHIC FACTOR AMGEN INC. (US) 2000-06-15 WO disclosed
WO-2000018914-A2 NOVEL DKR POLYPEPTIDES AMGEN INC. (US) 2000-04-06 WO disclosed
US-6034230-A MODULATE INFLAMMATORY HEART DISEASE. AMGEN CANADA INC. (CA) 2000-03-07 US disclosed
WO-2000009692-A1 NOVEL PEPTIDES CAPABLE OF MODULATING INFLAMMATORY HEART DISEASE AMGEN CANADA INC. (US) 2000-02-24 WO disclosed
WO-1999063089-A1 CYCLIN E2 GENES AND PROTEINS AMGEN INC. (US) 1999-12-09 WO disclosed